GH axis & cellular ageing
Longevity is really two research areas sharing a shelf: growth-hormone secretagogues that act on the GH axis, and cellular-ageing compounds studied around telomerase and redox metabolism. The secretagogues are the larger group and the one where mechanism differences are most often misunderstood. Priced and shipped in CAD, for laboratory and research use only.
The GH secretagogues split into two mechanisms that are routinely conflated. CJC-1295 is a GHRH analogue — it acts on the GHRH receptor. Ipamorelin, GHRP-2 and GHRP-6 are ghrelin mimetics acting on GHS-R1a. Because the two pathways are complementary, they are frequently studied in combination — hence the CJC-1295 + ipamorelin stack. Growth hormone secretagogues explained is the category primer.
CJC-1295 is stocked both with and without DAC (drug affinity complex), and the difference is pharmacokinetic rather than mechanistic: DAC binds albumin and extends half-life substantially, which changes dosing frequency in research protocols. CJC-1295 with or without DAC covers the trade-off, and ipamorelin vs CJC-1295 compares across the mechanism line.
Epithalon is a synthetic tetrapeptide from Russian pineal-gland research, studied around telomerase activity. NAD+ sits on the redox and cellular-energy side — related to the energy category's mitochondrial focus, but studied at the coenzyme level. Epithalon vs MOTS-c covers where those two research areas meet.
hCG is stocked here as an LH analogue studied around HPG-axis signalling. It is not a GH compound and does not belong to either group above — it sits in this category because the research context is endocrine-axis signalling. Related HPG compounds are in foundational. The longevity and GH protocol sets out how this category is structured in research designs.
NAD+ dosage — research dosing notes
What the literature actually reports on NAD+ dosage: the 750 mg six-hour intravenous protocol from Grant 2019, the oral NR and NMN dose-ranging trials, why infusion rate matters more than total milligrams, and reconstitution math for a 500 mg vial.
Epithalon vs MOTS-c — longevity peptides compared
Epithalon vs MOTS-c: telomerase and circadian signalling against mitochondrial AMPK activation — mechanisms, half-life, and what the published research actually supports for each.
Ipamorelin vs CJC-1295 — compared
Ipamorelin vs CJC-1295: two different receptors, two different half-lives, two different depths of human data. A research comparison of the ghrelin-receptor agonist and the long-acting GHRH analog.
GHRP-2 vs GHRP-6 — compared
GHRP-2 vs GHRP-6 compared across sequence, receptor pharmacology, half-life, GH response and appetite — including where the common claim that GHRP-2 avoids hunger breaks down against the published data.
CJC-1295 dosage — research dosing notes
A literature review of CJC-1295 dosage: the weight-scaled weekly doses used in the published human trials of the DAC form, the half-life data behind that cadence, and reconstitution math for a 10 mg research vial.
Ipamorelin dosage — research dosing notes
A research overview of ipamorelin dosage: the reconstitution math, the intravenous doses and twice-daily cadence reported in the literature, and the ~2-hour half-life context — framed strictly as a laboratory-research reference, not medical advice.
Research & educational use only. This page is informational and does not constitute medical advice or a therapeutic claim.

Canada Peptides
EPITHALON 10MG
LONGEVITY SIGNAL
$40.00·Longevity